(Q34023737)

30 July 2017

title

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

1 reference

J-F Rossi

1

1 reference

30 July 2017

S Négrier

2

1 reference

30 July 2017

N D James

3

1 reference

30 July 2017

I Kocak

4

1 reference

30 July 2017

R Hawkins

5

1 reference

30 July 2017

H Davis

6

1 reference

30 July 2017

U Prabhakar

7

1 reference

30 July 2017

X Qin

8

1 reference

30 July 2017

P Mulders

9

1 reference

30 July 2017

B Berns

10

1 reference

30 July 2017

language of work or name

English

0 references

publication date

31 August 2010

1 reference

British Journal of Cancer

30 July 2017

published in

1 reference

30 July 2017

volume

103

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

1154-1162

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605872

30 July 2017

exact match

0 references

cites work

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Sorafenib in advanced clear-cell renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Targeted therapy for metastatic renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Metastatic renal carcinoma comprehensive prognostic system

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Therapeutic options in the management of renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

The role of C-reactive protein as a prognostic indicator in advanced cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Pretreatment serum markers and lymphocyte response to interleukin-2 therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.

5 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605872

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605872

CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605872

Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2967052

Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma

29 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605872

C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality

21 January 2018

1 reference

12 December 2020

Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator

1 reference

12 December 2020

Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6

1 reference

12 December 2020

Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group

1 reference

12 December 2020

Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605872

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference